- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 271/06 - 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
Patent holdings for IPC class C07D 271/06
Total number of patents in this class: 977
10-year publication summary
|
51
|
48
|
99
|
111
|
103
|
100
|
74
|
60
|
61
|
19
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| BASF SE | 19740 |
62 |
| Syngenta Participations AG | 4970 |
43 |
| PTC Therapeutics, Inc. | 492 |
33 |
| Bristol-myers Squibb Company | 5080 |
29 |
| Receptos LLC | 65 |
28 |
| Aurigene Oncology Limited | 64 |
16 |
| The Scripps Research Institute | 1364 |
15 |
| PI Industries Ltd | 147 |
15 |
| Merck Sharp & Dohme LLC | 3689 |
14 |
| Astellas Pharma Inc. | 1145 |
12 |
| Abbvie Inc. | 1808 |
11 |
| Theravance Biopharma R&D IP, LLC | 550 |
11 |
| Bayer Cropscience AG | 2241 |
10 |
| FUJIFILM Corporation | 27102 |
10 |
| Modernatx, Inc. | 1181 |
10 |
| Novartis AG | 11238 |
9 |
| Sumitomo Chemical Company, Limited | 8808 |
9 |
| Aurigene Discovery Technologies Limited | 120 |
9 |
| Cytokinetics, Inc. | 259 |
9 |
| Shionogi & Co., Ltd. | 914 |
9 |
| Other owners | 613 |